WellStone, the largest and most comprehensive mental health provider in North Alabama, has ordered 1,000 Trauma Autoimmune Indicator (TAI) tests from iXpressGenes. This innovative, science-based tool will be integrated into patient care to enhance trauma screening. It allows for early intervention by detecting trauma-induced diseases before symptoms appear, thereby revolutionizing the detection, prevention and treatment of PTSD and trauma-related diseases.
“Mental health treatment has traditionally been reactive, addressing symptoms only after they appear,” said Jeremy Blair, LMFT and CEO of WellStone. “With TAI screening from iXG, we now have a proactive approach that enables us to identify biological markers of trauma before symptoms develop. This partnership marks a crucial step forward in improving patient outcomes and reducing long-term health risks.”
iXG has found that prolonged stress and trauma can lead to unique inflammation and autoimmune responses in the body. With a simple blood test, iXG can identify specific genetic biomarkers that indicate the potential development of trauma-related diseases — including PTSD, autoimmune disorders and cardiovascular conditions — before symptoms appear.
John Schmitt, CEO of iXG and a seasoned combat veteran with two decades of experience, remarks, “The integration of our TAI test by WellStone marks a pivotal development in the field of trauma-informed care. Acknowledging that trauma has both psychological and physiological ramifications, WellStone is taking a proactive approach by prioritizing early identification and continuous monitoring of patients. This strategy enables the detection of chronic inflammation, which can precede trauma-related disorders such as PTSD, thereby facilitating timely interventions. By addressing these issues before they manifest as symptoms as well as giving clinicians an important tool to inform the effectivity of ongoing care, WellStone is not just reacting to trauma but is actively reshaping the landscape of trauma care.”
“This adoption signals significant market demand leading up to our commercial release — and we’re thrilled to meet that need and truly begin to support clinicians and improve people’s lives,” Schmitt adds.
As a leader in mental health services, WellStone serves more than 12,000 clients annually across North Alabama, providing counseling, crisis care and community-based support to children and adults. By adopting iXG’s TAI screening, WellStone can offer earlier intervention, improve treatment outcomes, and enhance ongoing patient care, ensuring a more comprehensive approach to trauma-related care.
For more information on iXpressGenes and the TAI test, visit www.ixpressgenes.com.
About iXpressGenes:
iXG is transforming mental health care with cutting-edge biomarker technology designed for both early detection and continuous monitoring of trauma-related diseases, including PTSD. Unlike a one-time solution, iXG provides mental health professionals with an objective diagnostic aid, helping track the underlying physiology and impacting mental health over time through a simple blood test. This gives providers deeper insights into patients’ progress, enabling more informed, personalized treatment decisions. Designed for veterans, first responders and all survivors of trauma, iXG enhances diagnosis and long-term care management confidence.
About Wellstone:
WellStone is a 501(c)3 nonprofit organization and North Alabama’s mental healthcare leader, serving children, adolescents and adults in Madison and Cullman counties and surrounding communities. They offer a wide range of services for every phase of life, serving more than 12,000 clients per year and operating 12 facilities across North Alabama.
https://www.ixpressgenes.com/